Actively Recruiting

Phase 2
Age: 50Years +
FEMALE
ID07407647

Vaginal DHEA for Women With Gynecologic and Gastrointestinal Cancer After Radiation

Led by Ohio State University Comprehensive Cancer Center · Updated on 2026-04-21

25

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of vaginal DHEA, a hormone replacement therapy, to improve vaginal health in women who have undergone radiation treatment for gynecologic, anal, or rectal cancers. Radiation to the abdomen can change the vaginal microbiome and cause symptoms such as dryness, burning, itching, bleeding, and pain during urination or sexual intercourse. This phase II trial aims to test the feasibility and side effects of vaginal DHEA for managing these symptoms in menopausal women after radiation therapy. Participants will receive daily vaginal doses of DHEA for three months, provided their disease does not progress and they do not experience unacceptable side effects. Throughout the study, vaginal swab samples will be collected to analyze changes in the vaginal microbiome. The study will also explore how the treatment affects vaginal exam findings, sexual function, and quality of life. During the trial, women will undergo regular vaginal exams, complete surveys about sexual function and symptoms, and provide vaginal swabs for microbiome analysis. Researchers will monitor for adverse events and changes in vaginal health and sexual distress from the start of treatment through 12 weeks. The total treatment period is three months, with ongoing assessments to evaluate the safety and impact of vaginal DHEA.

CONDITIONS

Brief Title

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Who Can Participate

Age: 50Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women with anal, rectal, cervical, vaginal, or vulvar cancer receiving external beam radiation alone or with brachytherapy with curative intent
  • Concurrent or prior chemotherapy allowed
  • Any prior gynecologic surgery allowed
  • Rectal surgery including lower anterior resection and abdominoperineal resection allowed
  • Menopausal women defined as age over 50 with no menses for 12 months or bilateral oophorectomy
Not Eligible

You will not qualify if you...

  • Patients with scleroderma, mixed connective tissue disorder, or lupus
  • Patients who have received prior pelvic radiation
  • Undiagnosed abnormal genital bleeding unrelated to current diagnosis or treatment
  • History of endometrial cancer or endometrial hyperplasia
  • Use of estrogen alone injectable or progestin implant therapy within 3 months before study entry
  • Use of estrogen pellet or progestin injectable drug within 6 months before study entry
  • Use of oral estrogen, progestin, DHEA, or intrauterine progestin within 8 weeks before study entry
  • Use of vaginal estrogen, transdermal estrogen with or without progestin, vaginal hyaluronic acid, or pro-estrogenic herbal treatments within 4 weeks before study entry
  • History of breast cancer
  • Patients receiving palliative radiation therapy
  • Patients who do not meet menopause criteria

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - 3 months

Participants receive vaginal DHEA once daily for 3 months in the absence of disease progression or unacceptable toxicity. Vaginal swab sample collection and surveys are conducted throughout the treatment period.

Trial Site Locations

Total: 1 location

1

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States, 43210

Actively Recruiting

Loading map...

Research Team

T

The Ohio State University Comprehensive Cancer Center

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

1

Similar Trials

Low Anterior Resection Syndrome: Retrograde Enema Program ve...

Low Anterior Resection Syndrome

Actively Recruiting

1 location

Prospective Randomized Validation of Adaptive Radiotherapy i...

Gynecological Tumor

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here